

# Spondylolisthesis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/S3264720896EEN.html>

Date: May 2024

Pages: 139

Price: US\$ 6,499.00 (Single User License)

ID: S3264720896EEN

## Abstracts

The 7 major spondylolisthesis markets reached a value of US\$ 17.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 29.5 Billion by 2034, exhibiting a growth rate (CAGR) of 4.79% during 2024-2034.

The spondylolisthesis market has been comprehensively analyzed in IMARC's new report titled "Spondylolisthesis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Spondylolisthesis refers to a medical disorder in which one of the vertebrae in the spinal column slides out of its proper position onto the vertebra below it. This can occur in any part of the spine, but generally, it takes place in the lower back (lumbar spine). The prominent symptoms of the ailment include severe back pain or nerve congestion, resulting in leg discomfort or numbness. Individuals suffering from spondylolisthesis may also experience muscle spasms in the hamstring (back thigh muscles), difficulty walking or standing for long periods, back stiffness, pain while bending over, weakness or tingling in the foot, etc. In severe cases, this condition may impair a person's quality of life by limiting mobility and impacting emotional well-being. The diagnosis of the illness is mainly made by reviewing the reported clinical features, medical history, and a physical test. A healthcare provider may also perform numerous other examinations, such as spinal X-rays, magnetic resonance imaging, computed tomography, etc., to look for misplaced bones or rule out further possible soft tissue diseases.

The rising cases of bone fractures or cracks which weaken the vertebrae, thereby enhancing their likelihood of slipping forward, backward, or over a bone below, are primarily driving the spondylolisthesis market. In addition to this, the expanding geriatric population, who are more prone to degenerative spine conditions due to wear and tear

on the spine, is also bolstering the market growth. Moreover, the widespread adoption of nonsteroidal anti-inflammatory drugs, such as ibuprofen and naproxen, which target the intervertebral joints and the nerve root to reduce pain, is acting as another significant growth-inducing factor. In line with this, the inflating application of epidural steroid injections that can be injected directly into the affected area to diminish swelling and control pressure on the larger nerves quickly is further propelling the market growth. Additionally, the emerging popularity of non-fusion spinal decompression surgery for treating the ailment since it aids in preserving the motion of the spine, lowering the risk of adjacent segment disease, and relieving neurological symptoms, is expected to drive the spondylolisthesis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the spondylolisthesis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for spondylolisthesis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the spondylolisthesis market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

## Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the spondylolisthesis market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the spondylolisthesis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current spondylolisthesis marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

### Key Questions Answered in this Report:

Market Insights

How has the spondylolisthesis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the spondylolisthesis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the spondylolisthesis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of spondylolisthesis across the seven major markets?

What is the number of prevalent cases (2018-2034) of spondylolisthesis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of spondylolisthesis by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with spondylolisthesis across the seven major markets?

What is the size of the spondylolisthesis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of spondylolisthesis?

What will be the growth rate of patients across the seven major markets?

### Spondylolisthesis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for spondylolisthesis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the spondylolisthesis market?

What are the key regulatory events related to the spondylolisthesis market?

What is the structure of clinical trial landscape by status related to the spondylolisthesis market?

What is the structure of clinical trial landscape by phase related to the spondylolisthesis market?

What is the structure of clinical trial landscape by route of administration related to the spondylolisthesis market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 SPONDYLOLISTHESIS - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 SPONDYLOLISTHESIS - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 SPONDYLOLISTHESIS - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (?2018-2034?)
  - 7.2.4 Epidemiology by Gender (?2018-2034?)
  - 7.2.5 Diagnosed Cases (?2018-2034?)
  - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (?2018-2034?)
  - 7.3.4 Epidemiology by Gender (?2018-2034?)
  - 7.3.5 Diagnosed Cases (?2018-2034?)
  - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (?2018-2034?)
  - 7.4.4 Epidemiology by Gender (?2018-2034?)
  - 7.4.5 Diagnosed Cases (?2018-2034?)
  - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (?2018-2034?)
  - 7.5.4 Epidemiology by Gender (?2018-2034?)
  - 7.5.5 Diagnosed Cases (?2018-2034?)
  - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (?2018-2034?)
  - 7.6.4 Epidemiology by Gender (?2018-2034?)
  - 7.6.5 Diagnosed Cases (?2018-2034?)
  - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (?2018-2034?)
  - 7.8.4 Epidemiology by Gender (?2018-2034?)
  - 7.8.5 Diagnosed Cases (?2018-2034?)
  - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (?2018-2034?)
  - 7.9.4 Epidemiology by Gender (?2018-2034?)
  - 7.9.5 Diagnosed Cases (?2018-2034?)
  - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

## **8 SPONDYLOLISTHESIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 SPONDYLOLISTHESIS - UNMET NEEDS**

## **10 SPONDYLOLISTHESIS - KEY ENDPOINTS OF TREATMENT**

## **11 SPONDYLOLISTHESIS - MARKETED PRODUCTS**

- 11.1 List of Spondylolisthesis Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Drug Name – Company Name
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.



## **12 SPONDYLOLISTHESIS - PIPELINE DRUGS**

### 12.1 List of Spondylolisthesis Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 NVD001 - Novadip Biosciences

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

#### 12.1.2 AK 1320 MS - Asahi Kasei Pharma Corp

##### 12.1.2.1 Drug Overview

##### 12.1.2.2 Mechanism of Action

##### 12.1.2.3 Clinical Trial Results

##### 12.1.2.4 Safety and Efficacy

##### 12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. SPONDYLOLISTHESIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. SPONDYLOLISTHESIS – CLINICAL TRIAL LANDSCAPE**

### 14.1 Drugs by Status

### 14.2 Drugs by Phase

### 14.3 Drugs by Route of Administration

### 14.4 Key Regulatory Events

## **15 SPONDYLOLISTHESIS - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Spondylolisthesis - Market Size

##### 15.2.1.1 Market Size (2018-2023)

##### 15.2.1.2 Market Forecast (2024-2034)

#### 15.2.2 Spondylolisthesis - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (2018-2023)

##### 15.2.2.2 Market Forecast by Therapies (2024-2034)

### 15.3 Market Scenario - United States

- 15.3.1 Spondylolisthesis - Market Size
  - 15.3.1.1 Market Size (2018-2023)
  - 15.3.1.2 Market Forecast (2024-2034)
- 15.3.2 Spondylolisthesis - Market Size by Therapies
  - 15.3.2.1 Market Size by Therapies (2018-2023)
  - 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Spondylolisthesis - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Spondylolisthesis - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Spondylolisthesis - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Spondylolisthesis - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Spondylolisthesis - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Spondylolisthesis - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Spondylolisthesis - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Spondylolisthesis - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Spondylolisthesis - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Spondylolisthesis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Spondylolisthesis - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Spondylolisthesis - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Spondylolisthesis - Access and Reimbursement Overview

## 15.8 Market Scenario - Spain

### 15.8.1 Spondylolisthesis - Market Size

#### 15.8.1.1 Market Size (2018-2023)

#### 15.8.1.2 Market Forecast (2024-2034)

### 15.8.2 Spondylolisthesis - Market Size by Therapies

#### 15.8.2.1 Market Size by Therapies (2018-2023)

#### 15.8.2.2 Market Forecast by Therapies (2024-2034)

### 15.8.3 Spondylolisthesis - Access and Reimbursement Overview

## 15.9 Market Scenario - Japan

### 15.9.1 Spondylolisthesis - Market Size

#### 15.9.1.1 Market Size (2018-2023)

#### 15.9.1.2 Market Forecast (2024-2034)

### 15.9.2 Spondylolisthesis - Market Size by Therapies

#### 15.9.2.1 Market Size by Therapies (2018-2023)

#### 15.9.2.2 Market Forecast by Therapies (2024-2034)

### 15.9.3 Spondylolisthesis - Access and Reimbursement Overview

## **16 SPONDYLOLISTHESIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 SPONDYLOLISTHESIS MARKET - SWOT ANALYSIS**

### 17.1 Strengths

### 17.2 Weaknesses

### 17.3 Opportunities

### 17.4 Threats

## **18 SPONDYLOLISTHESIS MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Spondylolisthesis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/S3264720896EEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S3264720896EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

